Andrea Gaedigk1, Christa Coetsee. 1. Section of Developmental Pharmacology and Experimental Therapeutics, Children's Mercy Hospital & Clinics, 2401 Gillham Road, Kansas City, MO 64108, USA. agaedigk@cmh.edu
Abstract
OBJECTIVE: The highly polymorphic CYP2D6 gene locus has been extensively scrutinised in the major ethnic populations, but little is known about the locus for many indigenous and unique admixed populations, including the Coloureds of South Africa. This study aimed at characterising the CYP2D6 gene locus in Coloured subjects and predict their phenotype status. METHODS: CYP2D6 genotyping was performed on 99 Coloured subjects by long-range polymerase chain reaction (PCR) and PCR restriction fragment length polymorphism (RFLP). Testing included 25 allelic variants as well as gene duplications. Novel alleles were cloned and sequenced. A novel strategy for CYP2D7/2D6 hybrid gene detection is described. RESULTS: Thirteen alleles had a frequency of = 1%, three were infrequent (<1%) and 16 of the tested alleles were not detected. CYP2D6*5 had a frequency of 17.2%, one of the highest ever observed in any population. Two novel alleles, CYP2D6*64 and *65, were identified. In addition, four samples carried CYP2D7/2D6 hybrid genes, of which one matched the CYP2D6*66 allele of a resequenced Caucasian control subject. CYP2D6*66 is similar to CYP2D6*16, but its putative recombination point is further upstream. Genotyping identified three poor metabolisers (3%; predicted incidence 6.6%), and 12% of the population had an activity score of 0.5 indicative of intermediate metabolism. CONCLUSIONS: The Coloured population has a unique composition of alleles and a distinct frequency distribution. The preliminary data presented suggest decreased CYP2D6 activity compared with Caucasians. Follow-up studies including both genotyping and phenotyping will need to be conducted to further assess the relationship between genotype and phenotype in this population of complex ancestry.
OBJECTIVE: The highly polymorphic CYP2D6 gene locus has been extensively scrutinised in the major ethnic populations, but little is known about the locus for many indigenous and unique admixed populations, including the Coloureds of South Africa. This study aimed at characterising the CYP2D6 gene locus in Coloured subjects and predict their phenotype status. METHODS:CYP2D6 genotyping was performed on 99 Coloured subjects by long-range polymerase chain reaction (PCR) and PCR restriction fragment length polymorphism (RFLP). Testing included 25 allelic variants as well as gene duplications. Novel alleles were cloned and sequenced. A novel strategy for CYP2D7/2D6 hybrid gene detection is described. RESULTS: Thirteen alleles had a frequency of = 1%, three were infrequent (<1%) and 16 of the tested alleles were not detected. CYP2D6*5 had a frequency of 17.2%, one of the highest ever observed in any population. Two novel alleles, CYP2D6*64 and *65, were identified. In addition, four samples carried CYP2D7/2D6 hybrid genes, of which one matched the CYP2D6*66 allele of a resequenced Caucasian control subject. CYP2D6*66 is similar to CYP2D6*16, but its putative recombination point is further upstream. Genotyping identified three poor metabolisers (3%; predicted incidence 6.6%), and 12% of the population had an activity score of 0.5 indicative of intermediate metabolism. CONCLUSIONS: The Coloured population has a unique composition of alleles and a distinct frequency distribution. The preliminary data presented suggest decreased CYP2D6 activity compared with Caucasians. Follow-up studies including both genotyping and phenotyping will need to be conducted to further assess the relationship between genotype and phenotype in this population of complex ancestry.
Authors: Hongwu Shen; Minxia M He; Houfu Liu; Steven A Wrighton; Li Wang; Bin Guo; Chuan Li Journal: Drug Metab Dispos Date: 2007-04-30 Impact factor: 3.922
Authors: T M Dodgen; C De J Labuschagne; A van Schalkwyk; F E Steffens; A Gaedigk; A D Cromarty; M Alessandrini; M S Pepper Journal: Pharmacogenomics J Date: 2015-10-27 Impact factor: 3.550
Authors: J Steven Leeder; Andrea Gaedigk; Krista J Wright; Vincent S Staggs; Sarah E Soden; Yvonne S Lin; Robin E Pearce Journal: Clin Transl Sci Date: 2022-08-23 Impact factor: 4.438
Authors: Keneuoe Cecilia Nthontho; Andrew Khulekani Ndlovu; Kirthana Sharma; Ishmael Kasvosve; Daniel Louis Hertz; Giacomo Maria Paganotti Journal: Pharmgenomics Pers Med Date: 2022-06-21
Authors: Carola R Röhrich; Britt I Drögemöller; Ogechi Ikediobi; Lize van der Merwe; Nelis Grobbelaar; Galen E B Wright; Nathaniel McGregor; Louise Warnich Journal: AIDS Res Hum Retroviruses Date: 2016-01-29 Impact factor: 2.205
Authors: Andrea Gaedigk; Lazara Karelia Montane Jaime; Joseph S Bertino; Anick Bérard; Victoria M Pratt; L Dianne Bradfordand; J Steven Leeder Journal: Front Pharmacol Date: 2010-10-04 Impact factor: 5.810
Authors: Tyren M Dodgen; Warren E Hochfeld; Heidi Fickl; Sahle M Asfaha; Chrisna Durandt; Paul Rheeder; Britt I Drögemöller; Galen E B Wright; Louise Warnich; Christiaan D J Labuschagne; Antoinette van Schalkwyk; Andrea Gaedigk; Michael S Pepper Journal: BMC Med Genet Date: 2013-01-29 Impact factor: 2.103
Authors: Louise Warnich; Britt I Drögemöller; Michael S Pepper; Collet Dandara; Galen E B Wright Journal: Curr Pharmacogenomics Person Med Date: 2011-09
Authors: Tyren M Dodgen; Arinda Eloff; Connie Mataboge; Louw J L Roos; Werdie C W van Staden; Michael S Pepper Journal: Appl Transl Genom Date: 2015-05-14